Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response

You Are Here : Home Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response

Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response
September, 420

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

Leave a Reply

Your email address will not be published.

Recent News

Goro Healthcare partners with Demophorius in the UAE and Qatar
December,321

Goro Healthcare launches Neopausil® in the United Arab Emirates
July,321

Tanyx® obtain MOHAP registration approval
January,1021

Goro Healthcare signs an exclusive distribution agreement with The OTClab and Perfect Care Phamra
September,820

Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response
September,420

FDA announces first of its kind program to communicate patient reported outcomes from oncology clinical trials
July,120
TOP
0
    0
    Your Cart
    Your cart is empty
    Continue Shopping